Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy

Clin Nucl Med. 2016 Jan;41(1):50-2. doi: 10.1097/RLU.0000000000000971.

Abstract

A 57-year-old woman diagnosed with ectopic Cushing syndrome was found to have a 111In-octreotide-avid corticotropin-producing pancreatic neuroendocrine tumor with liver metastases. She was treated with 4 induction and 4 maintenance cycles of 177Lu-DOTATATE, which normalized her serum corticotropin levels and dramatically reduced the size of the pancreatic primary and liver metastases.

Publication types

  • Case Reports

MeSH terms

  • Adrenocorticotropic Hormone / biosynthesis*
  • Female
  • Humans
  • Liver Neoplasms / secondary
  • Middle Aged
  • Neuroendocrine Tumors / metabolism*
  • Neuroendocrine Tumors / pathology
  • Neuroendocrine Tumors / radiotherapy*
  • Octreotide / analogs & derivatives*
  • Octreotide / therapeutic use
  • Organometallic Compounds / therapeutic use*
  • Pancreatic Neoplasms / metabolism*
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / radiotherapy*
  • Receptors, Peptide / metabolism*

Substances

  • Organometallic Compounds
  • Receptors, Peptide
  • Adrenocorticotropic Hormone
  • lutetium Lu 177 dotatate
  • Octreotide